Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase‐positive non‐small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report

Alectinib treatment is effective in patients with anaplastic lymphoma kinase (ALK) gene rearrangement‐positive non‐small cell lung cancer (NSCLC; hereafter ALK‐positive NSCLC) who exhibit central nervous system (CNS) relapse and poor performance status (PS). Lorlatinib treatment is effective upon fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Kota, Yokota, Yusuke, Isojima, Toshihito, Fujii, Mayumi, Hasui, Kengo, Chen, Yu, Saito, Kensuke, Takahata, Takenori, Kindaichi, Seiko, Sato, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173452/
https://www.ncbi.nlm.nih.gov/pubmed/34123384
http://dx.doi.org/10.1002/rcr2.796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173452/
https://www.ncbi.nlm.nih.gov/pubmed/34123384
http://dx.doi.org/10.1002/rcr2.796

Ejemplares similares